Tanzania Lung Cancer Therapeutics Market Report 2022 to 2030

Tanzania Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Tanzania Lung Cancer Therapeutics Market will reach a value of $24 Mn from $12 Mn in 2022, growing at a CAGR of 9% during 2022-2030. The Lung Cancer Therapeutics Market in Tanzania is dominated by a few domestic pharmaceutical companies such as Dawa Limited, Africure Pharmaceuticals Limited, and Incepta Pharmaceuticals. The Lung Cancer Therapeutics Market in Tanzania is segmented into different types of cancer and different therapy types. Some of the major factors affecting the Tanzania lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies, and the presence of highly efficient drugs.

ID: IN10TZPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Vishwa Modhia

Buy Now

Tanzania Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Tanzania Lung Cancer Therapeutics market will reach a value of $24 Mn from $12 Mn in 2022, growing at a CAGR of 9% during 2022-30.

Tanzania is a low-income, developing country in East Africa bordering the Indian Ocean. In 2018, the age-standardized rate per 100,000 people for all ages was 0.9 for males and 0.2 for females. Cancer is Tanzania's biggest noncommunicable disease, followed by diabetes and cardiovascular disease. Tanzania has seen a steady and large increase in cancer cases. According to the International Agency for Research on Cancer (IARC), 42,060 new instances of cancer are identified in Tanzania each year, with a high mortality rate of 28,610 deaths per year, indicating that many patients are detected at advanced stages.

According to the latest WHO data published in 2020 Lung cancer deaths in Tanzania reached 159 or 0.05% of total deaths. The age-adjusted Death Rate is 0.60 per 100,000 population ranks Tanzania 181^st in the world. Tanzania's government spends 3.8% of its GDP on healthcare.

Tanzania Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

In Tanzania, 19.8 % of men and 2.2 % of women smoke daily. In 2017, Tanzania had 96 % of its people utilising solid fuels, which causes lung cancer. Aga Khan Hospital Dar es Salaam, Bugando Medical Centre, Kilimanjaro Christian Medical Centre, and the Ocean Road Cancer Institute are also major cancer centres. Tanzania is developing a regional cooperation strategy. In addition, the country receives international assistance in the form of concessional loans. These aspects could boost Tanzania's Lung Cancer Therapeutics market.

Market Restraints

A cancer diagnosis is upsetting anywhere in the world, but in Tanzania, it is frequently a death sentence. Because 80 % of cases are discovered at an advanced stage, supportive treatment and symptom control are frequently all that can be provided. Tanzania has very few cancer treatment centres. Furthermore, not all patients can travel significant distances to obtain therapy. Many people would rather not be treated at all. The route to acquire treatment, the financial burden, the availability of cancer facilities, the availability of chemotherapy and radiation therapy, the lack of information, and the stigma associated with cancer in Tanzania are all factors that contribute to people not seeking medical attention. These factors may deter new entrants into the Tanzania Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Dawa Limited: Dawa Limited is a Tanzanian pharmaceutical company that specializes in the production and distribution of generic medicines. The company offers a range of lung cancer treatments including chemotherapy drugs
Africure Pharmaceuticals Limited: Africure Pharmaceuticals Limited is a Tanzanian pharmaceutical company that specializes in the production and distribution of pharmaceutical products. The company offers a range of lung cancer treatments including chemotherapy drugs
Incepta Pharmaceuticals Tanzania Limited: Incepta Pharmaceuticals Tanzania Limited is a subsidiary of Incepta Pharmaceuticals, a Bangladeshi pharmaceutical company. The company offers a range of lung cancer treatments including chemotherapy drugs
Medisel Tanzania Limited: Medisel Tanzania Limited is a Tanzanian pharmaceutical company that specializes in the distribution of pharmaceutical products. The company offers a range of lung cancer treatments including chemotherapy drugs
Quality Chemicals Tanzania Limited: Quality Chemicals Tanzania Limited is a Tanzanian pharmaceutical company that specializes in the production and distribution of pharmaceutical products. The company offers a range of lung cancer treatments including chemotherapy drugs

Healthcare Policies and Reimbursement Scenarios

The Tanzania Food and Drugs Authority (TFDA) is the regulatory authority in Tanzania responsible for the approval and regulation of therapeutic items, including lung cancer therapies. The TMDA is now in charge of regulating the quality, safety, and efficacy of medicines, medical equipment, diagnostics, biocides, and tobacco products. Most Tanzanians lack insurance and are impoverished. While not all cancer centres provide free care, there is still a long waiting list for cancer treatment, especially considering the scarcity of institutions equipped with the necessary diagnostic and therapeutic technology. A person with cancer may have to wait months after being diagnosed to begin treatment at a public institution.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.